Nemaura Healthcare Secures $20 Million Non-Dilutive Financial loan to Accelerate Business enterprise Development

Loughborough, England, Feb. 11, 2021 (Globe NEWSWIRE) — Nemaura Clinical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a health-related engineering corporation centered on producing and commercializing non-invasive wearable diagnostic units and supporting personalized way of living coaching systems, announces it has secured a $20 million non-dilutive, non-convertible mortgage that was secured by Firm assets. The personal loan does not consist of warrants or other fairness securities.

“This mortgage significantly strengthens our money position and provides our cash to a lot more than $34M, significantly in excess of our recent burn off charge of fewer than $1.5M for every quarter.Importantly, this financing does not dilute shareholders, however continue to presents substantial runway to accelerate our general development,” mentioned Dr. Faz Chowdhury, Nemaura’s CEO. “We take pleasure in the ongoing sturdy assistance from our financial institution, Chicago Venture Associates.”

About Nemaura Health care, Inc.

Nemaura Health-related Inc. is a professional medical know-how organization developing and commercializing non-invasive wearable diagnostic units.The Enterprise is currently commercializing sugarBEAT® and proBEAT™.sugarBEAT®, a CE mark accepted Class IIb clinical product, is a non-invasive and versatile steady glucose monitor (CGM) furnishing actionable insights derived from true time glucose measurements and everyday glucose trend knowledge, which might assistance men and women with diabetic issues and pre-diabetes to better take care of, reverse, and avoid the onset of diabetic issues.Nemaura has submitted a PMA (Premarket Approval Software) for sugarBEAT® to the U.S. Food and drug administration.proBEAT™ brings together non-invasive glucose knowledge processed working with synthetic intelligence and a electronic health care subscription company and is expected to be launched in the U.S. as a typical wellness products.

The Corporation sits at the intersection of the worldwide Form 2 diabetic issues sector that is envisioned to reach virtually $59 billion by 2025, the $50+ billion pre-diabetic current market, and the wearable overall health-tech sector for fat loss and wellness programs that is estimated to arrive at $60 billion by 2023.

For extra information, make sure you stop by www.NemauraMedical.com.


Cautionary Assertion Regarding Forward-Searching Statements:

The statements in this press release that are not historical details might represent forward-hunting statements that are centered on present expectations and are matter to dangers and uncertainties that could trigger genuine potential effects to differ materially from those people expressed or implied by these types of statements. These dangers and uncertainties include things like, but are not constrained to, the start of proBEAT™ in the US, threats connected to regulatory position and the failure of long run growth and preliminary advertising and marketing attempts, Nemaura’s capability to safe added commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ means to produce, market place and offer proBEAT™, the availability of significant supplemental equity or credit card debt cash to guidance its research, enhancement and product or service commercialization things to do, and the results of its study, progress, regulatory approval, promoting and distribution strategies and procedures, which include all those programs and tactics related to the two proBEAT™ digital health and fitness, and sugarBEAT®. There can be no assurance that the enterprise will be capable to access a component of or any of the worldwide market place for CGM with its items/services. The Fda reserves the correct to re-assess their selection that proBEAT™ qualifies as a general wellness merchandise must it come to be informed of any concerns this kind of as pores and skin irritation or other adverse functions from the product, as properly as any misuse impacting affected person security, and any other reason as the Fda may see fit at its discretion to decide the merchandise does not fit the definition of a standard wellness product. These and other challenges and uncertainties are discovered and described in a lot more depth in Nemaura’s filings with the United States Securities and Trade Fee, which include, without limitation, its Annual Report on Form 10-K for the most recently finished fiscal 12 months, its Quarterly Reports on Kind 10-Q, and its Present Studies on Sort 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.

Get in touch with:

Jules Abraham
Core IR
917-885-7378
[email protected]